Trilexium is a novel therapy in early stage pre-clinical development with potential application across a range of different cancer types, and the potential to combine effectively with established targeted therapies
Trilexium has demonstrated pre-clinical activity in cancers with high unmet need and relatively limited treatment options including renal cancer and several childhood cancers.
Trilexium (TRXE-009-1) was identified using Novogen’s proprietary VAL-ID medicinal chemistry program. In vitro efficacy studies have confirmed broad and strong activity against renal cancer, liver cancer, sarcoma, lung cancer, and prostate cancer, among other adult indications. In addition, several paediatric cancers were also indicated as highly responsive including osteosarcoma, neuroblastoma, and diffuse intrinsic pontine glioma (DIPG). DIPG is associated with one of the worst outcomes of any childhood cancer with no chemotherapeutic yet to demonstrate clinical efficacy.
Trilexium is in early-stage development and Novogen is working with global R&D collaborators with whom we aim to identify biomarkers of activity, delve deeper into the mechanism of action, and complete proof of concept studies assessing differentiated cancer cell populations and matched cancer stem-like populations. Animal studies have confirmed that TRXE-009-1 is active against tumours growing in animals, but these studies used a non-clinical formulation. Further animal studies will follow on from an extensive formulation development program currently underway with a formulation organisation in Canada to generate a clinically acceptable formulation of TRXE-009-1.
TRXE-009-1 is undergoing a formulation program that aims to identify a clinically acceptable drug-product.
More Publications and Presentations